Place-Based Disparities in Treatment and Time-to-Initiation for Head and Neck Cancer.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41865265.
- Also identified by DOI 10.1002/ohn.70214.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the United States, 72,000+ adults are diagnosed with head and neck cancer (HNC) annually. Despite improving outcomes overall, place-based disparities persist. While existing evidence has emphasized disparities at diagnosis, less is known about disparities in patterns of care that differ after diagnosis. Observational, repeated cross-sectional design. Surveillance, Epidemiology, and End Results (SEER) case data (2018-2022). We analyzed our first mutually exclusive set of binary outcomes related to the type of treatment received, which were categorized as surgery only, surgery with adjuvant radiotherapy, definitive chemoradiation, radiation or chemotherapy alone, or no treatment. Our second set of binary outcomes related to time from diagnosis to treatment initiation: 0 to 29, 30 to 59, 60 to 89, and 90+ days. Linear probability and multinomial regression models adjusted for tumor site, stage, sociodemographics, and geography to estimate the association between residing in a low-income county (<80k median household income) and differences in the probability of each outcome. Our sample included 70,468 HNC cases. We found no place-based differences for adjuvant or definitive treatment. Compared to patients in high-income counties, patients in low-income counties were 1.1% points less likely to receive surgery only (-2.2, -0.1) and 1.0% points more likely to receive radiation or chemotherapy alone (0.1, 1.8); and 2.1% points less likely to begin treatment within 0 to 29 days (-3.7, -0.4) and 1.4% points more likely to delay treatment until 60 to 89 days (0.5, 2.3). Our findings warrant implementing and evaluating system-level interventions to promote access to high-quality, timely HNC treatment in low-income communities.